<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982316</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10345</org_study_id>
    <nct_id>NCT03982316</nct_id>
  </id_info>
  <brief_title>Telehealth Behavioral Migraine Management</brief_title>
  <acronym>TeleBMM</acronym>
  <official_title>Telehealth Behavioral Migraine Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to develop the protocol and obtain feasibility and acceptability
      information for Telehealth Behavioral MIgraine Management in a single-arm pre-post pilot
      study. I aim recruit 20 people with migraine from the Montefiore Headache Center in the Bronx
      NY. Participants will receive the 12-week protocol including a mobile app headache diary, an
      online patient manual with interactive vignettes, 4 50-minute telehealth sessions, and 3
      15-minute check-ins.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of TeleBMM</measure>
    <time_frame>Week 0 through Week 12</time_frame>
    <description>Number of treatment components participants complete (out of 20)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-rated satisfaction</measure>
    <time_frame>Post-treatment survey at Week 12</time_frame>
    <description>Patient-rated satisfaction (acceptability) with the program on a Likert-type scale ranging from 0 (&quot;Not at all satisfied&quot;) to 4 (&quot;Very satisfied&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Migraine Specific)</measure>
    <time_frame>Change from Pre-treatment (Week 0) to Post-treatment (Week 12)</time_frame>
    <description>Score on the MSQ v 2.1, a 14-item survey assessing quality of life in people with migraine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache frequency</measure>
    <time_frame>Slope change from Week 0 to Week 12</time_frame>
    <description>Participants complete a daily headache diary, on which each 7 day week they denote whether they have had a headache attack.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Telehealth Behavioral Migraine Management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive weekly online education sessions in the following categories: Relaxation, Early Warning Signs, Triggers, Medication Adherence, Reducing Migraine Impact, Stress Management, Biofeedback, and Relapse Prevention. Participants will receive four monthly 50-minute telehealth sessions with a doctoral psychology student in a clinical health psychology program covering these topics, and three check-ins to enhance adherence to behavior change strategies. Participants will complete a daily headache diary throughout the course of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telehealth Behavioral Migraine Management</intervention_name>
    <description>1) Weekly online modules; 2) Monthly 50 minute telephone calls; 3) 3 15-minute telephone check ins.</description>
    <arm_group_label>Telehealth Behavioral Migraine Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician diagnosis of migraine

          -  Current self-reported symptoms meeting the International Classification for Headache
             Disorders -- 3 criteria for migraine

          -  Self-reported between 4 and 20 headache days/month

          -  Aged 18-65

          -  Can read English

          -  Capacity to consent

        Exclusion Criteria:

          -  Psychiatric illness that would interfere with study participation

          -  Meeting criteria for probable medication overuse headache
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth K Seng, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeshiva University/Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth K Seng, Ph.D.</last_name>
    <phone>646-592-4368</phone>
    <email>Elizabeth.Seng@einstein.yu.edu</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 8, 2019</study_first_submitted>
  <study_first_submitted_qc>June 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Elizabeth Seng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

